5 completed, 3 terminated, 2 recruiting, 1 withdrawn. 6 Phase 1, 4 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 3, Recruiting 2, Completed 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 3 | 3 | Completed 2, Withdrawn 1 |
Follow Heidelberg Pharma AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma HDP-101 - Multiple Myeloma and Other Plasma Cell Neoplasms | Phase 1 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 15 | 2026-03-17 | 2026-04-14 |
| Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma HDP-101 - Multiple Myeloma, Plasma Cell Disorder | Phase 1 / Phase 2 | Recruiting | Heidelberg Pharma AG | 78 | 2022-02-07 | 2026-09-17 |
| REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT Iodine (124I) Girentuximab - Renal Cell Carcinoma, Kidney Cancer | Phase 3 | Withdrawn | Heidelberg Pharma AG | 2017-12-01 | 2017-12-22 | |
| Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours WX-037, WX-554 - Advanced Solid Tumours | Phase 1 | Terminated | Heidelberg Pharma AG | 13 | 2013-07-01 | 2014-05-16 |
| Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours WX-554 - Advanced Solid Tumours | Phase 1 / Phase 2 | Terminated | Heidelberg Pharma AG | 41 | 2012-03-01 | 2014-05-16 |
| Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer WX-671, placebo - Metastatic Breast Cancer | Phase 2 | Completed | Heidelberg Pharma AG | 132 | 2008-07-01 | 2014-02-28 |
| Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody 124-Iodine-cG250 (124I-cG250), CT - Renal Cell Carcinoma, Kidney Cancer | Phase 3 | Completed | Heidelberg Pharma AG | 226 | 2008-03-01 | 2018-10-02 |
| Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma Chimeric monoclonal antibody cG250, Sunitinib malate - Renal Cell Carcinoma (RCC) | Phase 1 | Terminated | Ludwig Institute for Cancer Research | 8 | 2008-02-01 | 2022-10-12 |
| Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery gemcitabine hydrochloride, Serine Proteinase Inhibitor WX-671 - Pancreatic Cancer | Phase 2 | Completed | Heidelberg Pharma AG | 95 | 2007-04-01 | 2012-03-29 |
| Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer girentuximab, placebo - Kidney Cancer | Phase 3 | Completed | Heidelberg Pharma AG | 864 | 2004-07-01 | 2018-11-27 |
| Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies WX-UK1 in combination with Capecitabine - Advanced Malignancies | Phase 1 | Completed | Heidelberg Pharma AG | 33 | 2004-05-01 | 2008-01-24 |
Carcinoma, Renal Cell (4) · Kidney Neoplasms (3) · Multiple Myeloma (2) · Neoplasms, Plasma Cell (2) · Breast Neoplasms (1) · Mycobacterium Infections, Nontuberculous (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
G250 monoclonal antibody (3) · upamostat (2) · Capecitabine (1) · Gemcitabine (1) · Iodine (1) · N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride (1) · Sunitinib (1)
United States (6) · Germany (3) · Brazil (2) · Hungary (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Belgium (1) · Canada (1) · China (1) · Israel (1) · Italy (1) · Poland (1) · Romania (1) · Russia (1)
Arie Belldegrun, MD, FACS (1) · Carola Mala, PhD (1) · Chaitanya Divgi, MD (1) · Lori Goldstein, MD (1) · Nadia Harbeck, MD (1) · Pia Kloepfer, MD (1) · Ruth Plummer, MD (1) · Udai Banerji, MD (1)